Iterum (ITRM, $0.63) denied approval by FDA for UTI Treatment
Iterum Therapeutics plc said that it will not get approval for the current form of its new drug application for oral sulopenem.
According to the Food and Drug Administration (FDA), additional data are required and the company should conduct at least one more well-controlled clinical trial for its treatment of adult women with uncomplicated urinary tract infections. FDA mentioned that it is willing to work with Iterum on the design of clinical trials in order to address the issues the FDA identified.
However, Iterum CEO Corey Fishman said the company is “disappointed in this outcome and believe that the data package submitted was adequate for the approval of oral sulopenem,” . Fishman added that they will still assess the points raised in the CRL for discussion with the FDA to determine an “expeditious path forward."
ITRM in -12.18% downward trend, falling for three consecutive days on May 11, 2022
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ITRM declined for three days, in 234 of 257 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Current price $0.22 crossed the support line at $1.12 and is trading between $1.12 support and $-3.19 support lines. Throughout the month of 04/12/22 - 05/13/22, the price experienced a -27% Downtrend. During the week of 05/06/22 - 05/13/22, the stock fell -12%.
The Aroon Indicator for ITRM entered a downward trend on May 13, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ITRM's RSI Indicator exited the oversold zone, 33 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ITRM advanced for three days, in 157 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ITRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 84%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.7.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ITRM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ITRM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.798) is normal, around the industry mean (23.274). P/E Ratio (0.000) is within average values for comparable stocks, (114.687). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.614). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (298.537).
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
The average market capitalization across the Biotechnology Industry is 1.6B. The market cap for tickers in the group ranges from 2.5K to 240B. NVO holds the highest valuation in this group at 240B. The lowest valued company is IMUND at 2.5K.
The average weekly price growth across all stocks in the Biotechnology Industry was -6.02%. For the same Industry, the average monthly price growth was -21.27%, and the average quarterly price growth was -32.51%. IVBT experienced the highest price growth at 86.5%, while EMMA experienced the biggest fall at -60.75%.
- 3/31/22 6:39 AM: Iterum Therapeutics (ITRM, $0.36) is a top weekly loser for penny stocks, falling -17.74%
- 3/23/22 4:50 AM: Iterum Therapeutics (ITRM, $0.44) is a top weekly gainer for penny stocks, rising +27.54%
- 3/3/22 7:26 AM: Iterum Therapeutics (ITRM, $0.39) is a top weekly gainer for penny stocks, rising +15.04%
The average weekly volume growth across all stocks in the Biotechnology Industry was 47.71%. For the same stocks of the Industry, the average monthly volume growth was -20.79% and the average quarterly volume growth was 2.5%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the Volume Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 37%. During the last month, the daily ratio of advancing to declining volumes was 1.07 to 1.
10 stocks in the group of tickers confirmed the positive outlook based on the RSI indicator with average odds of 87%.
The most notable companies in this group are Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Cel-Sci Corp (ASE:CVM).
The average market capitalization across the group is 762.5M. The market cap for tickers in the group ranges from 18.6M to 4.1B. NVAX holds the highest valuation in this group at 4.1B. The lowest valued company is IDRA at 18.6M.
The average weekly price growth across all stocks in the group was -8.1%. For the same group, the average monthly price growth was -27.67%, and the average quarterly price growth was -58%. AGEN experienced the highest price growth at -2.4%, while IDRA experienced the biggest fall at -16.58%.
- 5/14/22 4:23 AM: Idera Pharmaceuticals (IDRA, $0.35) is a top weekly loser for penny stocks, falling -16.58%
- 5/12/22 5:38 AM: Pluristem Therapeutics (PSTI, $1.43) is a top weekly loser for penny stocks, falling -15.88%
- 5/10/22 5:36 AM: Genetic Technologies (GENE, $1.32) is a top weekly loser for penny stocks, falling -16.82%
The average weekly volume growth across all stocks in the group was 25.16%. For the same stocks of the group, the average monthly volume growth was 46.59% and the average quarterly volume growth was 36.43%
- 5/14/22 4:16 AM: The volume for Compugen stock increased for four consecutive days, resulting in a record-breaking daily growth of 84% of the 65-Day Volume Moving Average
- 4/20/22 8:52 AM: The volume for Idera Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 349% of the 65-Day Volume Moving Average
- 3/19/22 4:43 AM: The volume for Agenus stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows